SCHEMBL2635397

SCHEMBL2635397

NC(=O)C(Oc1cc(C(=O)O)cc2cc(Cl)cc(Cl)c12)c1cccnc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 3/20 0.39
RAB9A P51151 4/20 0.36
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A2 P23975 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 2/20 0.36
LMNA P02545 3/20 0.35
SLC6A3 Q01959 1/20 0.35
APP P05067 1/20 0.35
GAA P10253 1/20 0.35
HCAR3 P49019 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
HTT P42858 2/20 0.34
KMT2A Q03164 5/20 0.34
MEN1 O00255 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636005 0.80 S1PR2 (0.35) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL2635422 0.79 PPARA (0.51) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL5660114 0.72 ALDH1A1 (0.44) TRPM8ALDH1A1SLC6A4SLC6A2SMN1; SMN2
SCHEMBL2635398 0.71 NOTUM (0.60) RAB9ANPC1KMT2AMEN1POLB
SCHEMBL10957411 0.70 LMNA (0.51) TRPM8RAB9AALDH1A1NPC1NFKB1
SCHEMBL2636158 0.69 MAPK1 (0.55) RAB9AALDH1A1HPGDLMNAHTT
SCHEMBL14744021 0.69 SYK (0.43) TRPM8RAB9AALDH1A1NPC1NFKB1
SCHEMBL2635856 0.68 PPARA (0.48) ALDH1A1LMNAGAAKMT2ANPSR1
SCHEMBL14743805 0.68 GPBAR1 (0.43) TRPM8RAB9AALDH1A1NPC1LMNA
SCHEMBL3262463 0.68 NOTUM (0.44) ALDH1A1SLC6A4SLC6A2SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US claimed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP claimed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO claimed
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 TRPM8 469/4885RAB9A 2053/4885ALDH1A1 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.